Question 1

Who are the top researchers at Sierra Eye Associates?

Accepted Answer

Ranked on the quality score, Arshad M. Khanani, Carl J. Danzig and Aamir A Aziz lead among researchers whose main affiliation is Sierra Eye Associates.

Question 2

What are the most cited papers from Sierra Eye Associates?

Accepted Answer

The most cited paper from Sierra Eye Associates is "Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials" (Jeffrey S Heier et al., 2022), with 742 citations. Next come "Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial" (364) and "Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema" (290).

Question 3

Which research topics does Sierra Eye Associates publish most on?

Accepted Answer

By volume in 2022-now: Retinal Diseases and Treatments, Retinal Development and Disorders, Ophthalmology and Visual Impairment Studies and Retinal Imaging and Analysis.

Question 4

Which keywords describe research at Sierra Eye Associates?

Accepted Answer

By fractional works in all years, weighted toward what it does more of than the world: Macular Degeneration, Diabetic Retinopathy, Vascular Endothelial Growth Factor, Intravitreal Injection, Inflammation, Oxidative Stress, Choroidal Thickness and Retinal Pigment Epithelium.

Question 5

Which fields of science does Sierra Eye Associates work in?

Accepted Answer

In all years, 80% of research at Sierra Eye Associates is in Health Sciences, 15% in Life Sciences. Its largest fields are Medicine (78%), Biochemistry, Genetics and Molecular Biology (10%), Environmental Science (3%). It does 2.8× the world's share of Health Sciences.

Question 6

Is Sierra Eye Associates's research output growing?

Accepted Answer

Output in 2022-2025 was 28% lower than in 2018-2021.